IDH3A and central nervous system cancer: STR compared to biopsy was associated with significantly reduced 2-year mortality in patients with low-grade glioma [23] and infratentorial pediatric high-grade gliomas [24], 1-year mortality in GBM [39], and improved OS in patients with isocitrate dehydrogenase-wild-type GBM [26] and low-grade glioma [22].